WallStreetZenWallStreetZen

NASDAQ: JSPR
Jasper Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for JSPR

Based on 3 analysts offering 12 month price targets for Jasper Therapeutics Inc

Min Forecast
$1.50+206.75%
Avg Forecast
$3.83+683.84%
Max Forecast
$7.00+1,331.49%

Should I buy or sell JSPR stock?

Based on 3 analysts offering ratings for Jasper Therapeutics Inc.

Hold
Strong Buy
0 analysts 0%
Buy
1 analysts 33.33%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their JSPR stock forecasts and price targets.

JSPR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-15
lockedlocked$00.00+00.00%2026-04-01
lockedlocked$00.00+00.00%2026-03-23

1 of 1

Forecast return on equity

Is JSPR forecast to generate an efficient return?

Company
-1,322.85%
Industry
92.48%
Market
176.74%
JSPR's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is JSPR forecast to generate an efficient return on assets?

Company
-212.32%
Industry
27.29%
JSPR is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

JSPR earnings per share forecast

What is JSPR's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$1.41
Avg 2 year Forecast
-$1.50
Avg 3 year Forecast
-$0.88

JSPR revenue forecast

What is JSPR's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

JSPR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
JSPR$0.49$3.83+683.84%Hold
ICU$3.47$8.00+130.55%Strong Buy
LEXX$0.57$1.50+164.08%Buy
CRIS$0.36$17.00+4,596.13%Buy
CYCN$3.27N/AN/A
View Top Biotech Stocks

Jasper Therapeutics Stock Forecast FAQ

Is Jasper Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: JSPR) stock is to Hold JSPR stock.

Out of 3 analysts, 0 (0%) are recommending JSPR as a Strong Buy, 1 (33.33%) are recommending JSPR as a Buy, 2 (66.67%) are recommending JSPR as a Hold, 0 (0%) are recommending JSPR as a Sell, and 0 (0%) are recommending JSPR as a Strong Sell.

If you're new to stock investing, here's how to buy Jasper Therapeutics stock.

What is JSPR's earnings growth forecast for 2026-2028?

(NASDAQ: JSPR) Jasper Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.52%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.21%.

Jasper Therapeutics's earnings in 2026 is -$55,734,000.On average, 10 Wall Street analysts forecast JSPR's earnings for 2026 to be -$39,380,326, with the lowest JSPR earnings forecast at -$81,596,729, and the highest JSPR earnings forecast at -$9,700,898. On average, 9 Wall Street analysts forecast JSPR's earnings for 2027 to be -$42,051,222, with the lowest JSPR earnings forecast at -$129,171,724, and the highest JSPR earnings forecast at -$3,821,566.

In 2028, JSPR is forecast to generate -$24,558,810 in earnings, with the lowest earnings forecast at -$50,209,495 and the highest earnings forecast at -$2,645,699.

What is JSPR's revenue growth forecast for 2026-2028?

(NASDAQ: JSPR) Jasper Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.8%.

Jasper Therapeutics's revenue in 2026 is $0.On average, 8 Wall Street analysts forecast JSPR's revenue for 2026 to be $0, with the lowest JSPR revenue forecast at $0, and the highest JSPR revenue forecast at $0. On average, 5 Wall Street analysts forecast JSPR's revenue for 2027 to be $0, with the lowest JSPR revenue forecast at $0, and the highest JSPR revenue forecast at $0.

In 2028, JSPR is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is JSPR's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: JSPR) forecast ROA is -212.32%, which is lower than the forecast US Biotechnology industry average of 27.29%.

What is JSPR's Price Target?

According to 3 Wall Street analysts that have issued a 1 year JSPR price target, the average JSPR price target is $3.83, with the highest JSPR stock price forecast at $7.00 and the lowest JSPR stock price forecast at $1.50.

On average, Wall Street analysts predict that Jasper Therapeutics's share price could reach $3.83 by May 15, 2027. The average Jasper Therapeutics stock price prediction forecasts a potential upside of 683.84% from the current JSPR share price of $0.49.

What is JSPR's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: JSPR) Jasper Therapeutics's current Earnings Per Share (EPS) is -$2.68. On average, analysts forecast that JSPR's EPS will be -$1.41 for 2026, with the lowest EPS forecast at -$2.91, and the highest EPS forecast at -$0.35. On average, analysts forecast that JSPR's EPS will be -$1.50 for 2027, with the lowest EPS forecast at -$4.61, and the highest EPS forecast at -$0.14. In 2028, JSPR's EPS is forecast to hit -$0.88 (min: -$1.79, max: -$0.09).

What is JSPR's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: JSPR) forecast ROE is -1,322.85%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.